🆕New research from the @hammond-lab.bsky.social The team demonstrate that TPM3 is a hypoxia-inducible gene in TNBC that supports F-actin organisation. TPM3 loss impaired motility & invasion in hypoxic TNBC cells, while not affecting viability, underscoring its potential as a therapeutic target.

We were delighted to celebrate Sir Walter Bodmer's 90th birthday at a symposium held at Hertford College. Talks from some of Sir Bodmer's former students, colleagues, and collaborators reflected on his extraordinary career spanning seven decades.

Researchers have developed a novel OXPHOS inhibitor designed to reduce tumour hypoxia, a major cause of radiotherapy resistance. By reducing oxygen consumption in tumour cells, the compound increases oxygen availability within tumours, alleviating hypoxia & potentially increasing radiosensitivity.

It was a pleasure to host Dr Jemma Longley from @unisouthampton.bsky.social for our GO-PRECISE Seminar Series focused on early cancer detection & prevention. Dr Longley shared exciting insights from the VIOLET Study, which is looking at vaginal fluid biomarkers for early detection of ovarian cancer

📢 Join us: Research Assistant in Cancer Immunogenetics We have an exciting opportunity to join Prof. Ben Fairfax’s research group, focused on understanding how host immunity and genetic variation influence responses to cancer immunotherapy. See more details: www.oncology.ox.ac.uk/about-us/cur...

NEWS: Oxford researchers join €50m European study on heart health in cancer patients  Read more about this joint research project. @oncology.ox.ac.uk  

NEWS: Study reveals lifetime obesity exposure in cancer patients is widely underestimated Read about this new study from @oncology.ox.ac.uk 

There's still a few spaces left to attend our second annual Oxford Liver Cancer Centre of Excellence Symposium! Register before EOD today to secure your place! Details below 👇 @oncology.ox.ac.uk @medsci.ox.ac.uk @mplsoxford.bsky.social

EVENT: Health research showcase Organised by @oxfordbrc.bsky.social and @oxhealthbrc.bsky.social, this is an opportunity to enjoy hands-on activities while learning about research taking place in Oxford. Thur 28 May https://oxfordbrc.nihr.ac.uk/brc-event/health-research-showcase-event-2025/

NEWS: New funding to fast-track ultra-fast FLASH radiotherapy into the clinic The EPSRC-funded project aims to advance the technique that may reduce treatment side effects. @oncology.ox.ac.uk 

Prof Dan McGowan will play a key role in an EU-funded project looking at how medical and digital tech – in his case, routine PET scans - can help us detect heart problems in cancer patients quicker. 📰 www.ouh.nhs.uk/news/articles/2386 @oncology.ox.ac.uk @ihieurope.bsky.social

Our second annual Oxford Liver Cancer Centre of Excellence Symposium will focus on advancing scientific collaboration and ultimately improving outcomes for liver cancer! 🥼When: 14th May 🧪Where: Richard Doll Building @medsci.ox.ac.uk @oncology.ox.ac.uk www.eventbrite.co.uk/e/oxford-liv...

How can we make radiotherapy faster, safer, and more accessible? Dr Kristoffer Petersson has secured £1.87M in EPSRC funding to develop megavoltage photon FLASH radiotherapy technology, an ultra-fast approach that could reduce harm to healthy tissue while maintaining effectiveness.

MILI participant Abbi talks about Li Fraumeni Syndrome and her experience of joining the MILI trial: mili.octru.ox.ac.uk/hear-from-a-... To learn about the MILI trial and LFS, visit mili.octru.ox.ac.uk #TP53 #LiFraumeniSyndrome #LFS @oncology.ox.ac.uk @oxfordcancer.bsky.social

Calling all early career researchers with an @ouhospitals.bsky.social contract!   The OHSRC are offering grants of up to £10K to NHS staff (including honorary contracts) whose research will help patients of the OUH. Deadline: Wed 15 April   Apply ➡️ https://www.ouh.nhs.uk/researchers/grants/

🆕New research from the Petersson lab, published in the British Journal of Radiology The team studied FLASH vs conventional radiotherapy in muscle invasive bladder cancer models, demonstrating enhanced survival through effective dose escalation using FLASH.

Kicking off our 'New to Oxford' talks at #OxSymp26 today, Lucy Brooks @oncology.ox.ac.uk discusses how neurodevelopmental and injury programs shape glioblastoma and therapy response.

MILI participant Abbi talks about Li Fraumeni Syndrome and joining the MILI trial: www.instagram.com/p/DWULPq8gSM... To learn about the MILI trial and LFS, visit mili.octru.ox.ac.uk #TP53 #LiFraumeniSyndrome #LFS @oncology.ox.ac.uk @oxfordcancer.bsky.social

Published today in @natmed.nature.com, researchers from @ox.ac.uk & MUHAS, Tanzania have shown that a minimally invasive liquid biopsy test can diagnose Burkitt lymphoma rapidly and accurately in sub-Saharan Africa, where delays in traditional testing often prove fatal. @oxfordcancer.bsky.social

Why are some oesophageal cancers so difficult to treat? @oncology.ox.ac.uk researchers found the most aggressive tumours have high chromosomal instability - meaning cancer cells constantly make mistakes as they divide, helping them adapt and resist treatment. More info ⬇️

New research led by @eileenparkes.bsky.social and co-authored by DPhil in Cancer Science Alumnus, Bruno Beernaert @oncology.ox.ac.uk, has uncovered new insights into why the most aggressive oesophageal cancers are so difficult to treat. 👇 www.cancer.ox.ac.uk/news/new-res...

Celebrating some of the brilliant women in our team and the trailblazers who inspire them this International Day of Women and Girls in Science 👩‍🔬✨ Scroll through below ⬇️⬇️ #WomenInScience #InternationalDayOfWomenAndGirlsInScience

Aglaia Skolariki, 2nd year Clinical Research Training Fellow, is researching how abnormal cell division in aggressive cancers drives particular genetic changes. 👇#InternationalDayofWomenAndGirlsInScience2026 @medsci.ox.ac.uk @oncology.ox.ac.uk @oxcio.bsky.social www.cancer.ox.ac.uk/news/interna...

Our second annual Oesophagogastric Cancer Centre of Excellence Symposium will examine how recent advancements in research and clinical practice are contributing to improved patient outcomes. ✅Open to @ox.ac.uk researchers 📆March 6th, 9am to 5pm Register 👇 www.eventbrite.co.uk/e/oesophagog...

Every cancer is different. Every patient is unique. On #WorldCancerDay2026, meet the researchers helping shape more individualised cancer care. #UnitedByUnique

#ScientistSpotlight 🧪 This week we’re featuring Robert Watson, an Academic Clinical Lecturer in the Department of Oncology, University of Oxford. @ox.ac.uk @oncology.ox.ac.uk @medsci.ox.ac.uk

🆕Study launched to investigate whether insulin levels influence how women with the most common type of breast cancer respond to treatment. Trans-EndoNET will examine the relationship between insulin levels & response to aromatise inhibitors in women with ER+HER2- breast cancer.

The LFS UK 2025 conference took place last September, updating on studies from across the country, including MILI. Visit LFS UK 2025 to see the various presentations and update on the MILI trial tinyurl.com/d2dfm36x #TP53 #LiFraumeniSyndrome #LFS @oncology.ox.ac.uk @oxfordcancer.bsky.social

Researchers from the Jiang Group have published Phase Ia trial results for OVM-200, a novel cancer vaccine targeting survivin. The first-in-human trial, published in eClinicalMedicine, reports promising early safety & immunogenicity findings in patients with advanced solid tumours. buff.ly/ZLCqaGC

The Oxford Centre for Cancer Early Detection and Prevention (OxCODE) Funding Scheme is open! 🔎Pump-priming cancer early detection and prevention research 🧪Open to @ox.ac.uk researchers 💷£20K 1-year awards 📆Deadline: Fri 27 Feb More on the OxCODE website 👇 www.oxcode.ox.ac.uk/about/oxcode....

2025 in numbers. A year of research, teaching, and collaboration.

TrustedMDT is a multi-agent AI system designed to support cancer treatment planning. The tool is made up of three agents, integrated into Microsoft teams, that work in concert to summarise clinical records, determine disease stage & draft evidence-based treatment recommendations. @medsci.ox.ac.uk

Parkes lab pre-print alert! ‘TMEM33 deletion potentiates anti-tumor CD8⁺ T cell immunity.’ Led by mtjackson101.bsky.social. Full bluetutorial follows! 1/10 www.biorxiv.org/content/10.6...

New Vacancy: Postdoctoral Researcher in Bioinformatics & Human Tissue Modelling We have an exciting opportunity to join the O'Neill lab, contributing to a pioneering tissue-focused research programme aimed at enhancing cure rates for gastrointestinal cancers. www.oncology.ox.ac.uk/about-us/wor...

NEW: Oxford researchers have developed TrustedMDT, a multi-agent artificial intelligence (AI) system designed to support medical specialists during cancer treatment planning meetings. Find out more ⬇️

Congratulations to Kendra Perez-Smith, Translational Support Unit Manager, who has received an Outstanding Contribution to Sustainability Award for her innovation & leadership in establishing Lab QuTe: a department-wide network designed to reduce the environmental impact of clinical trials.

Researchers at @oncology.ox.ac.uk have developed TrustedMDT, a multi-agent AI system designed to support cancer treatment planning. TrustedMDT is made up of three AI agents that work in concert to summarise clinical records, determine disease stage & draft treatment recommendations. Read more ⬇️

Congratulations to Keaton Jones who has received a @wellcometrust.bsky.social Early Career Award 🔬 The funding will enable Keaton & his team to shed light on immunotherapy resistance in pancreatic cancer, a critical hurdle that, if overcome, could provide much needed new treatment options.

Congratulations to the team at Brighton and Sussex for recruiting 61 participants to SCOOT. @uhsussex.bsky.social @chestconsultant.bsky.social @oncology.ox.ac.uk #lungcancer #personalisedtherapy and #earlydiagnosis

In case you missed it! Sarah Blagden @oncology.ox.ac.uk featured in Channel 4’s Cancer Detectives: Finding the Cures last week, sharing ground-breaking precision-prevention research at Oxford! Read more ⬇️ @sarahblagden.bsky.social @medsci.ox.ac.uk www.cancer.ox.ac.uk/news/profess...

Oxford Professor Sarah Blagden, @oncology.ox.ac.uk appears in the first episode of Cancer Detectives: Finding the Cures on @Channel4 tonight! 📺 Watch at 9pm, Thurs 20 Nov, or stream on Channel 4. Brought to you by @CR_UK. #CancerDetectives #CancerPrevention www.channel4.com/programmes/c...

We’re thrilled to partner with Channel 4 on ‘Cancer Detectives: Finding the Cures’ - a new series which is shining a light on three trailblazing scientists taking on cancer, and explores how their work is changing patients’ lives right now. 👇 1/2

World’s first lung cancer prevention vaccine gets £2 million for clinical trial People at high risk of lung cancer will soon be able to receive the experimental vaccine, 'LungVax', designed to prevent the disease, in a world-first clinical trial. @medsci.ox.ac.uk @oxfordcancer.bsky.social

Next up in the Meet The MILI Team series, is Dr Schaida Schirwani. Dr Schirwani is a genetics consultant and is part of the MILI team at University Hospital Southampton. #LFS #LiFraumeni @uhsft.bsky.social @oncology.ox.ac.uk @oxfordcancer.bsky.social tp53.co.uk/lfs-tp53/

What if we could stop #Cancer before it even starts? Prof. Sarah Blagden @oncology.ox.ac.uk & PPI contributor Anna Fry discuss novel cancer prevention research on the @oxfordsparks.bsky.social podcast. 🎧 www.oxfordsparks.ox.ac.uk/podcasts/cou... @sarahblagden.bsky.social @medsci.ox.ac.uk

INTREPID is one of five interdisciplinary teams launched as part of a new UK initiative to transform disease research through the development of advanced human tissue models. The team will evaluate & optimise the use of patient-derived explants as tumour models. Learn more:

Funded PhD available working with us on tumour hypoxia and radiosensitivity at @oncology.ox.ac.uk @ox.ac.uk Closing date 2nd Dec www.oncology.ox.ac.uk/study-with-u...

Sruthi Shakthivel is a technician in the Translational Support Unit (TSU), a dedicated unit within @octooxford.bsky.social that focuses on the operational & scientific side of biological sample management in clinical trials. Sruthi shares insights on the mission of the TSU & what her role involves:

#WIMMReads Fairfax Group ( @bpfairfax.bsky.social ) map how genetic variation shapes monocyte gene expression and splicing across immune contexts 🧪 Read more 👇 doi.org/10.1038/s414... #Genomics #Immunology #Transcriptomics

Members of the Department of Oncology were at ESMO 2025 in Berlin last week to present their research, chair sessions, and network with collaborators. Read about some of the highlights from our department’s contributions to the congress: www.oncology.ox.ac.uk/news/esmo-2025